Spyre Therapeutics Secures $180M in Strategic Financial Move
Company Announcements

Spyre Therapeutics Secures $180M in Strategic Financial Move

An update from Spyre Therapeutics (SYRE) is now available.

Spyre Therapeutics, Inc. has announced a significant move in the financial markets, securing a $180 million private placement deal with institutional and accredited investors. Scheduled to close on March 20, 2024, this agreement will result in the sale of newly designated Series B Non-Voting Convertible Preferred Stock, each share of which is convertible into 40 shares of common stock. Furthermore, the company has adjusted its corporate framework to accommodate the new stock, ensuring that these preferred shares come with dividend rights and specific conversion limitations to maintain a balanced ownership structure. This strategic financial maneuver is aimed at bolstering the company’s position and providing a stable foundation for future growth.

For detailed information about SYRE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskSpyre Therapeutics Advances IBD Treatment Pipeline
TheFlySpyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
TheFlySpyre Therapeutics price target raised to $65 from $50 at Guggenheim
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App